BridgeBio Pharma, Inc. (BBIO) — Revenue
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $502.08M | +126.3% |
| 2024 | $221.90M | +2285.3% |
| 2023 | $9.30M | -88.0% |
| 2022 | $77.65M | +11.4% |
| 2021 | $69.72M | +745.1% |
| 2020 | $8.25M | -79.7% |
| 2019 | $40.56M | — |
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $502.08M | +126.3% |
| 2024 | $221.90M | +2285.3% |
| 2023 | $9.30M | -88.0% |
| 2022 | $77.65M | +11.4% |
| 2021 | $69.72M | +745.1% |
| 2020 | $8.25M | -79.7% |
| 2019 | $40.56M | — |